Published in Medical Letter on the CDC and FDA, April 19th, 2006
With U.S. and world health experts now suggesting that the possibility of an avian flu pandemic in the near future is very real, Carrington's unique GelVac system, developed by Carrington's subsidiary, DelSite Biotechnologies, could make it possible to get more vaccines to more people, faster and more efficiently, than any other existing or imagined vaccine delivery system.
DelSite's GelVac avian flu vaccine is uniquely...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.